This site is intended for healthcare professionals
Magnifying glass on blue background; searching for results

Find disease awareness content and relevant supporting materials

Learning Zone 301 Events 9 News 19643 Drugs 41728 Trials 869 Guidelines 724 Journals 2048
Filter results
Sort by:
Relevance
to
Journals
Journal
31/08/19

IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis

Background: Hyperactivity of the IL-23/IL-17 axis is central to plaque psoriasis pathogenesis. Secukinumab, a fully human mAb that selectively inhibits IL-17A, is approved for treatment of psoriasis, psoriatic arthritis, and ankylosing spondylitis.

  • 1 min read
  • Source: Journal of Allergy and Clinical Immunology
Blue test tubes arranged in a line, disappearing into the background
Drug news
01/10/15

Phase III FUTURE 1 study of secukinumab for psoriatic arthritis is published in NEJM- Novartis

Novartis announced that results from the pivotal Phase III FUTURE 1 study for secukinumab in psoriatic arthritis (PsA) were published...

  • 1 min read
Blue test tubes arranged in a line, disappearing into the background
Drug news
09/11/15

Positive two year data for Cosentyx (secukinumab) from FUTURE 1 study for psoriatic arthritis- Novartis

Novartis announced new results for Cosentyx (secukinumab) showing no further progression in joint damage in 84% of patients with psoriatic...

  • 1 min read
Blue test tubes arranged in a line, disappearing into the background
Drug news
24/11/15

EU approves Cosentyx (secukinumab) for psoriatic arthritis- Novartis

Novartis announced that the European Commission (EC) has approved Cosentyx (secukinumab) for the treatment of people living with psoriatic arthritis...

  • 1 min read
Blue test tubes arranged in a line, disappearing into the background
Drug news
08/01/17

UK's NICE recommends use of Cosentyx (secukinumab) in active psoriatic arthritis- Novartis

The UK's National Institute for Health and Care Excellence is supporting use of Cosentyx (secukinumab), from Novartis, alone, or in...

  • 1 min read
Journals
Journal
30/06/17

Secukinumab in the Treatment of Psoriasis and Psoriatic Arthritis: A Review of the Literature

While there are several commercially available treatment options for psoriasis and psoriatic arthritis, there remains a large number of individuals who are refractory to current modalities.

  • 1 min read
  • Source: Skin Therapy Letter
Blue test tubes arranged in a line, disappearing into the background
Drug news
01/11/19

Cosentyx shows encouraging results versus Humira from first-of-its-kind head-to-head trial in psoriatic arthritis.-Novartis

Novartis, announced results from the EXCEED head-to-head trial comparing Cosentyx (secukinumab) to Humira (adalimumab) in patients with active psoriatic arthritis...

  • 1 min read
Journals
Journal
01/02/18

Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis

To assess the comparative effectiveness and safety of novel biologic therapies in psoriatic arthritis (PsA) and to establish the position of the non-anti-tumor necrosis factor α (TNF-α) biologic drugs in the treatment regimen of the disease.

  • 2 min read
  • Source: Rheumatology International
Blue test tubes arranged in a line, disappearing into the background
Drug news
23/10/15

CHMP recommends Cosentyx (secukinumab) to treat psoriatic arthritis and ankylosing spondylitis- Novartis

Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Cosentyx (secukinumab) in...

  • 1 min read
Blue test tubes arranged in a line, disappearing into the background
Drug news
20/04/17

UK NICE gives final appraisal recommending use of Cosentyx (secukinumab) in psoriatic arthritis- Novartis

The UK's National Institute for Health and Care Excellence has published its final appraisal which backs the use of Cosentyx...

  • 1 min read
See more